New drug aims to cut opioid use after heart and Weight-Loss surgery
NCT ID NCT07539623
First seen Apr 25, 2026 · Last updated Jun 22, 2026 · Updated 14 times
Summary
This study tests whether adding suzetrigine, a new non-opioid pain drug, to standard pain management can lower the amount of opioids needed after weight-loss or heart surgery. About 235 adults will be randomly assigned to receive either suzetrigine or a placebo alongside usual care. The main goal is to measure total opioid use and pain scores after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-OPERATIVE PAIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mount Sinai Morningside
RECRUITINGNew York, New York, 10025, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Suzetrigine
What this could lead to
If it works, this could offer a new way to manage post-surgery pain with fewer opioids, potentially reducing addiction risk and side effects.
What could go wrong
This is a phase 3 trial, but results may not apply to all surgeries or patients. The drug may not reduce opioid use enough or could have unknown side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.